Galapagos NV (GLPGF)
Galapagos NV is a biotechnology company focused on discovering and developing medicines in oncology and immunology, with its activities primarily centered in the United States and Europe. Its development pipeline includes GLPG3667, a phase 2 candidate being studied for dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at the point of care and in phase 1/2 trials for relapsed or refractory non-Hodgkin lymphoma; and GLPG5301, a BCMA CAR-T candidate also manufactured at the point of care and in phase 1/2 testing for relapsed or refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. Founded in 1999, Galapagos is headquartered in Mechelen, Belgium. Its common stock is listed on OTC Markets under the symbol GLPG.F.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-GLPG.F
|
$29.46
|
4.9% Upside
|
Fair
|
—
|
—
|
—
|
Great
|
—
|
—
|
—
|
0.0%
|
August 10, 2026
|
3.5x
|
0.5x
|
1.6x
|
1.934 B
|
-1.484 B
|
0.4%
|
62.1%
|
39.2
|
—
|
-63.6%
|
